Amicus Therapeutics FOLD
-
GlaxoSmithKline ([[GSK]] -1.5%) and Amicus Therapeutics announce they have commenced testing to compare the safety and efficacy of Amigal in an 18-month study related to the treatment of Fabry ...
GlaxoSmithKline ( GSK -1.5% ) and Amicus Therapeutics announce they have commenced testing to compare the safety and efficacy of Amigal in an 18-month study related to the treatment of Fabry disease. Post your comment!
-
Extraordinary medical coverage for an extraordinary CEO?… cure. By day, Crowley serves as CEO of Amicus Therapeutics ( FOLD ). Crowley also serves as an intelligence ..... on Wednesday, announcing his return to Amicus next month. Back in April, Amicus put out this release announcing that Crowley …
-
UPDATE 1- Amicus says US FDA removes clinical hold on Pompe drug
March 8 (Reuters) - Amicus Therapeutics Inc said U.S. health regulators removed the clinical hold on its treatment for Pompe disease and agreed to its plans to launch a new mid-stage study.
-
Dropping Coverage of Amicus
We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
-
New Morningstar Analyst Report - Amicus Therapeutics , Inc.
… Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders …
-
New Morningstar Analyst Report - Shire PLC
… in 2008 of Dynepo ( from Transkaryotic Therapies ) after lackluster sales , and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data . While Adderall XR's generic competition is a drag on the top line , Vyvanse is experiencing …
-
New Morningstar Analyst Report - Shire PLC
… in 2008 of Dynepo (from Transkaryotic Therapies) after lackluster sales, and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data.While Adderall XR's generic competition is a drag on the top line, Vyvanse is experiencing …
-
New Morningstar Analyst Report - Amicus Therapeutics , Inc.
… Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders …
-
A Banner Year for No-Moat Firms
… Inc. ENER 1.61 -18.57 -57.4 Progenics Pharmaceuticals, Inc. PGNX 10.81 -18.88 -56.26 Amicus Therapeutics , Inc. FOLD 1.31 -61.28 -51.38 Citigroup, Inc. C -20.48 -28.17 -50.07 MetroPCS Communications, Inc …
-
Amicus Regains Control of Weakened Pipeline
… value estimate in place following Amicus Therapeutics ' FOLD third-quarter results, despite ..... In conjunction with earnings, Amicus announced the termination of ..... clinical-stage drug candidates. Amicus regains international rights …